BioNexus Gene Lab Gross Profit Growth & History (BGLC)
BioNexus Gene Lab's gross profit was $1.1M for fiscal 2025.
View full BioNexus Gene Lab company overviewBioNexus Gene Lab annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.1M | −$204,304 | −15.84% |
| 2024 | 2024-12-31 | $1.3M | −$39,977 | −3.01% |
| 2023 | 2023-12-31 | $1.3M | $70,469 | +5.60% |
| 2022 | 2022-12-31 | $1.3M | −$1.0M | −44.46% |
| 2021 | 2021-12-31 | $2.3M | $547,118 | +31.81% |
| 2020 | 2020-12-31 | $1.7M | $1.7M | +2977.27% |
| 2019 | 2019-12-31 | $55,888 | $27,123 | +94.29% |
| 2018 | 2018-12-31 | $28,765 | — | — |
BioNexus Gene Lab quarterly gross profit
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12,982 | −$355,040 | −96.47% |
| Q1 2026 | 2026-03-31 | −$790 | −$344,283 | — |
| Q4 2025 | 2025-12-31 | −$3,983 | −$313,217 | — |
| Q3 2025 | 2025-09-30 | $377,685 | $51,149 | +15.66% |
| Q2 2025 | 2025-06-30 | $368,022 | $79,302 | +27.47% |
| Q1 2025 | 2025-03-31 | $343,493 | −$21,538 | −5.90% |
| Q4 2024 | 2024-12-31 | $309,234 | $42,679 | +16.01% |
| Q3 2024 | 2024-09-30 | $326,536 | −$27,796 | −7.84% |
| Q2 2024 | 2024-06-30 | $288,720 | −$50,994 | −15.01% |
| Q1 2024 | 2024-03-31 | $365,031 | −$3,866 | −1.05% |
| Q4 2023 | 2023-12-31 | $266,555 | −$72,671 | −21.42% |
| Q3 2023 | 2023-09-30 | $354,332 | $54,833 | +18.31% |
| Q2 2023 | 2023-06-30 | $339,714 | $75,743 | +28.69% |
| Q1 2023 | 2023-03-31 | $368,897 | $12,564 | +3.53% |
| Q4 2022 | 2022-12-31 | $339,226 | −$168,349 | −33.17% |
| Q3 2022 | 2022-09-30 | $299,499 | −$409,695 | −57.77% |
| Q2 2022 | 2022-06-30 | $263,971 | −$203,636 | −43.55% |
| Q1 2022 | 2022-03-31 | $356,333 | −$226,232 | −38.83% |
| Q4 2021 | 2021-12-31 | $507,575 | $124,571 | +32.52% |
| Q3 2021 | 2021-09-30 | $709,194 | $186,972 | +35.80% |
| Q2 2021 | 2021-06-30 | $467,607 | $308,317 | +193.56% |
| Q1 2021 | 2021-03-31 | $582,565 | −$72,742 | −11.10% |
| Q4 2020 | 2020-12-31 | $383,004 | $348,681 | +1015.88% |
| Q3 2020 | 2020-09-30 | $522,222 | $514,548 | +6705.08% |
| Q2 2020 | 2020-06-30 | $159,290 | $154,665 | +3344.11% |
| Q1 2020 | 2020-03-31 | $655,307 | $646,041 | +6972.17% |
| Q4 2019 | 2019-12-31 | $34,323 | $41,048 | — |
| Q3 2019 | 2019-09-30 | $7,674 | −$14,696 | −65.70% |
| Q2 2019 | 2019-06-30 | $4,625 | −$21,025 | −81.97% |
| Q1 2019 | 2019-03-31 | $9,266 | $21,796 | — |
| Q4 2018 | 2018-12-31 | −$6,725 | — | — |
| Q3 2018 | 2018-09-30 | $22,370 | — | — |
| Q2 2018 | 2018-06-30 | $25,650 | — | — |
| Q1 2018 | 2018-03-31 | −$12,530 | — | — |
BioNexus Gene Lab gross profit trends
Over the last five fiscal years, BioNexus Gene Lab's gross profit decreased from $1.7M to $1.1M, a change of −$634,606. The latest reported quarter, Q2 2026, shows $12,982.
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioNexus Gene Lab source filings ↗